Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

NEW ORLEANS – A trial designed to expand the market for Bayer HealthCare/Johnson & Johnson’s oral anticoagulant Xarelto (rivaroxaban) instead has highlighted that the drug has a worse bleeding profile than Sanofi-Aventis’ low molecular weight heparin Lovenox (enoxparin) in patients hospitalized with acute illnesses.

You may also be interested in...



Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market

Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.

Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation

Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.

Apixaban Study Halted - But It May Not Cause Much Damage To The Program

The APPRAISE-2 trial was stopped due to excess bleeding. But the study tested the drug as an add-on treatment in a high-risk population and in a marginal indication for the anticoagulant.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel